27 September 2016 - The TGA has approved a new use for Takeda's CD 30 receptor antagonist.

The TGA approved the use of brentuximab vedotin for the treatment of adult patients with CD30+ Hodgkin lymphoma at higher risk of relapse or progression following ASCT on 20 September 2016.

Read TGA approved Product Information for Adcetris